WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
Recruiting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * ability to understand study procedures and being willing to comply with them for the entire study length * diagnosis of lymphoma or sarcoma with new start or 1 year after completion of anthracycline therapy Exclusion Criteria: * LVEF \<50% at baseline, or prior confirmed history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm * Unwilling or unable to give written informed consent * Participants who have opted out of the Minnesota Research Authorization
About the study
The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG) can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors and smart watch based surveillance for cardiotoxicity is feasible and reliable.
What is being tested
- Electrocardiogram (procedure)
- Echocardiogram (procedure)
- LVEF echocardiogram (procedure)
- Apple Watch (other)
- Biospecimen collection (procedure)
- Questionnaires (other)
Sponsor: Mayo Clinic · Participants: 250 · Started: Jul 18, 2025
Contact the study team
- Tera Peck · Phone: 507-266-2123
- Clinical Trials Referral Office · Phone: 855-776-0015
Official record on ClinicalTrials.gov — NCT07058064
Locations in the U.S.
| Minnesota | Mayo Clinic in Rochester, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.